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Summary
The coming of age of lung transplantation is accompanied by an immunosuppressive armamentarium that has been brought forward from other
transplant indications. Widely employed on the basis of few small randomized studies, and mostly single-center experience or empirical expert
knowledge, anti-rejection therapeutic strategies in pulmonary transplantation have hardly been rigorously evaluated in large-scale prospective
international trials. This review compiles the available findings on the use of current immunosuppressants in clinical lung transplantation,
accentuating high level-of-evidence study results. Reporting on recent meeting and registry data, and assembling ongoing relevant trials from
international databases, this article serves as an update on the state of the art of immunosuppression in lung transplantation.
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The transplanted lung is an interface with the outside
world. Comprising an alveolar surface area of 100 m2 and an
air—blood diffusion barrier of 0.2 mm [1], the pulmonary
parenchyma forms the largest and most direct area of
exchange with themilieu exte´rieur in man. All particularities
in treating lung allograft recipients reflect these unique
circumstances. The perpetual exposure to infectious agents
and allergen from the environment is paralleled by a
continuous host immune surveillance from within. Conse-
quently, both infection and rejection markedly contribute to
patient attrition, arriving at twice the rates encountered in
cardiac transplantation: infectious complications and
chronic rejection at 3—5 years following engraftment
account for 9.7% versus 19.5% and 16% versus 28.5% of
deaths in heart and lung recipients, respectively [2,3]. The
survival half life (based on the international ISHLT registry)
after cardiac transplantation is 10, versus 5.2 years following
pulmonary engraftment [2,3].
Immunosuppressive therapy in lung transplant recipients
constantly navigates the narrow strait between Scylla and
Charybdis, epitomized by rejection and infection. The
required high load of immunosuppressants adds a cumulative§ This article is dedicated to Professor emeritus Harald Morr.
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depression and malignancy over time. With approximately
2000 annual transplants worldwide, and the majority of
centers performing<10 procedures per year, meaningful data
from large randomized trials is only tenaciously obtained. To
datenoconsensushas been reachedconcerning a standardized
immunosuppressive regimen, and none of the contemporarily
employed immunosuppressants in pulmonary transplantation
(Table 1) have been approved for this indication by the FDA.
The focus of this manuscript is the current state of the art
for pharmacological immunosuppression in lung transplanta-
tion, reflecting on available evidence from completed and
ongoing clinical trials.
2. Induction
Induction therapy consists of a brief regimen of intravenous
antibody therapy, targeting activated host lymphocytes. In
2008, around 54% of all pulmonary allograft recipients have
been exposed to induction of some kind [3]. These anti-
lymphocytic agents constitute a heterogenous class of drugs,
ranging from polyclonal anti-T-cell preparations (ALG, ATG) to
monoclonal agents, aimed at lymphocyte surface molecules
such as CD3 (OKT3), IL-2R/CD25 (basiliximab, daclizumab) or
CD52 (campath-1H). The use of polyclonal antibody prepara-
tions for induction has decreased to around 10%, while
interleukin-2-receptor antagonists (IL-2RAs) are increasingly
employed (around 37%); campath, a novel anti-CD52 mono-
clonal antibody, is used in around 6% of patients [3].Surgery. Published by Elsevier B.V. All rights reserved.
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Table 1
Currently employed immunosuppressive drugs in lung transplantation.
Immunosuppressive drug class Mode of action Comment
Polyclonal anti-lymphocyte antibody preparations
(equine, ATGAM; rabbit, thymoglobulin).
Substantial lymphocyte depletion. Decreasing role for induction therapy.
Risk of allergic reaction, cytokine-release
syndrome.
Monoclonal anti-lymphocyte antibody
preparation (mouse, OKT3).
Binds to CD3 (as part of the TCR), blocking
T-cell-activation and leading to lymphocyte depletion.
Rarely used for induction.
Cytokine-release syndrome.
Anti-cytokine receptor antibodies (humanized,
daclizumab; chimeric, basiliximab).
Non-depleting anti-IL-2R (CD25) antibodies. Low rate of adverse events.
Most commonly used induction agents.
campath-1H (alemtuzumab). Humanized monoclonal anti-CD52 antibody, inducing
complement- and antibody-dependent T-cell lysis.
Experience with this antibody in
induction therapy is still limited.
Corticosteroids (prednisone, prednisolone,
methylprednisolone).
Extensive transcriptional regulation (inhibition of
activator protein-1 and NF k-B) in lymphocytes and
non-immune cells, inducing immunosuppressive
and anti-inflammatory effects.
Standard component of induction,
maintenance and anti-rejection therapy.
Calcineurin inhibitors (CNI; cyclosporine A,
tacrolimus).
Transcription-inhibition of key-cytokines
(IL-2, IL-4, IFN-g, TNF-a).
In spite of major side effects (nephrotoxicity,
diabetogenicity, neurotoxicity, lipid disorders,
hypertension), CNI remain a cornerstone in
lung transplantation.
Antimetabolites (azathioprine,
mycophenolic acid).
Purine-synthesis blockers, targeting proliferating
lymphocytes.
Mycophenolic acid is replacing azathioprine
due to less toxicity and possibly better
efficacy. Together with CNI, antimetabolites
form the backbone for immunosuppressive
therapy in lung transplantation.
mTOR inhibitors (sirolimus, everolimus). Blocking G1-to-S-phase cell cycle progression,
targeting proliferating lymphocytes and
non-hematopoietic cells (e.g. smooth muscle cells).
Most recent immunosuppressive agents with
the potential to decrease the burden of
CNI-nephrotoxicity and BOS. However, their
distinct adverse event profile limits their
de novo use.Polyclonal antibody preparations contain equine (ATGAM)
or rabbit (Thymoglobulin) g-globulin fractions, directed
against human surface T- and B-cell-molecules [4]. When
binding to lymphocytes, they induce complement-dependent
cytolysis, resulting in substantial lymphocyte depletion [5].
Due to their xenogeneic nature, hypersensitivity responses
may develop after repeated exposures. Leucopoenia and
thrombocytopenia have to be monitored, and prophylactic
anti-CMV treatment should be initiated [6]. Based on the
analysis of ISHLT data, ATG/ALG-induction significantly
reduced the incidence of acute rejection (AR) during the
first year post-transplantation, compared to no induction or
IL-2RA-induction [3]. These registry findings reconfirm a
previous prospective, single-center study by Palmer et al. in
44 recipients of single or bilateral lung transplants, where the
incidence of biopsy-proven acute rejection was significantly
reduced in the presence of ATG-induction, versus no
induction [7]. Yet, rate of survival, infection or malignancy
at 2 years did not differ between these groups [7]. After 2
years, a trend toward a lower incidence of bronchiolitis
obliterans syndrome (BOS) was documented in the ATG-group
(20%) versus the non-induction arm (38%) [7].
Muromonab-CD3 (OKT3) is a mouse-anti-human-CD3
monoclonal antibody, which also acts by depleting human
T-cells from the circulation. Since CD3 is part of the T-cell
receptor complex, indispensable for lymphocyte activation,
binding of OKT3 may trigger cytokine-release syndrome, with
potentially life-threatening consequences [8]. Due to these
side effects, use of OKT3 as induction agent is declining.
Compared to ATG and daclizumab, induction with OKT3 did
not lead to improved incidence of freedom from acute
rejection or BOS at 2 years post-transplantation [9].
However, in this single-center, prospective study, rate ofbacterial infection was significantly higher in the group that
had been exposed to OKT3 [9].
In contrast to polyclonal antibody preparations and OKT3,
the two IL-2RA basiliximab (simulect) and daclizumab
(zenapax) show fewer side effects and are well tolerated.
Both antibodies are murine in origin, but have undergone
genetic engineering to replace part of the original amino acid
sequences by human protein: basiliximab represents a
chimerized (around 75% human protein), and daclizumab a
humanized (around 90% human protein) antibody.
During the last decade, several trials have analyzed the
impact of IL-2RA on acute rejection, infection, BOS and
survival, compared to no induction and/or ATG and/or OKT3
(Table 2). Although some studies have been prospective in
nature, they were limited by their small patient numbers and
single-center approach [9—12]. Retrospective studies, albeit
larger, were based on single-center data as well, mostly
comparing historical findings with contemporary patient
outcomes [13—15]. Taken together, and backed from the
most recent ISHLT registry reports [3,16], evidence seems to
be emerging that (i) induction therapy (either ALG/ATG or IL-
2RA) is associated with significantly less rejection episodes
than without induction; (ii) induction is associated with
better long-term survival; (iii) induction treatment has no
significant effect on freedom from BOS. As reflected in
ongoing prospective trials (Table 3: NCT00592306,
NCT00188825, NCT00105183) there is a need to further
clarify the role of induction regimen on the outcome of lung
transplantation.
First data are available with campath-1H (alemtuzumab)-
based induction in pulmonary transplant recipients [17].
However, these phase II results were obtained in a study
design employing induction with campath-1H versus ATG,
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Table 2
Key studies analyzing IL-2RA for induction therapy in lung transplantation.
Author, year Study details n Endpoint Result
Brock et al., 2001 [9] 4-year, controlled, prospective, single-center.
OKT3 versus ATG vsdaclizumab.
87 Infection, rejection,
survival, BOS.
Daclizumab had significantly less
infections. No difference for
other endpoints.
Hachem et al., 2004 [13] Retrospective analysis, single-center, at 3, 6,
12 months. Basiliximab versus ATG.
157 Acute rejection (AR), BOS. Significantly more patients with AR
and BOS under basiliximab vs ATG.
Borro et al., 2005 [10] Prospective, single-center. High-risk group
with basiliximab versus no induction.
15 AR, chronic rejection
(CR), survival.
Basiliximab with trend to lower AR
and CR and at 2 years marked
better survival.
Mullen et al., 2005 [11] 1-year, prospective, randomized, controlled,
single-center. ATG versus daclizumab.
50 Time to first rejection,
infection, survival, cost.
Daclizumab showed a trend toward
delay to first rejection and better
survival. Daclizumab with significant
more infections and CMV-infectionsa.
No difference in cost.
Burton et al., 2006 [14] Retrospective, single-center. ATG versus
daclizumab.
335 AR requiring treatment
(A2) and A3/A4.
Significantly less AR in the presence
of ATG vsdaclizumab.
Lischke et al., 2007 [12] 1-year, controlled, prospective,
single-center. ATG versus daclizumab.
25 Rejection, infection,
BOS, survival.
Freedom from AR significantly in
favor for daclizumab. No significant
differences for infection, BOS or
1-year-survival.
Ailawadi et al., 2008 [15] Retrospective, single-center, historical
comparison. ATG versus daclizumab.
163 AR, BO, death. Daclizumab associated with
significant less AP, less BO and
improved overall survival.
Hachem et al., 2008 [16] 4-year, retrospective cohort study from
the ISHLT registry. No induction versus
IL-2RA versus ATG.
3970 Survival (and incidence
of BOS).
Use of IL-2RA is associated with sig.
better graft survival. Both induction
groups have sig. fewer rejections,
but no difference between groups
on incidence of BOS. Both IL-2RA
and ATG show sig. higher incidence
of treated infections.
a Significantly higher CMV-mismatch in daclizumab arm.followed by tacrolimus near-monotherapy. At 6 months,
there were significantly fewer acute rejections in the
campath-1H group, compared to ATG [17].
3. Maintenance
In lung transplantation, maintenance immunosuppressive
therapy is based in the majority of patients on a triple
regimen [3] [18], composed of a calcineurin inhibitor (CNI;
cyclosporine A or tacrolimus), an anti-metabolite (azathiopr-
ine, mycophenolate mofetil or enteric-coated mycopheno-
late sodium) and steroids. As a fourth group, mammalian
target of rapamycin (mTOR) inhibitors (sirolimus, ever-
olimus) may be introduced, often in substitution for the CNI
or the anti-metabolite. In contrast to other perfused organ
transplants, there is very limited experience on steroid
withdrawal in lung allograft recipients [19,20]. Based on
most recent data (time period 2002—2007), tacrolimus and
mycophenolic acid were the most frequently used CNI and
anti-metabolite, respectively. At 1 year, 77% of recipients
were exposed to a CNI/anti-metabolite-combination, and
70% at 5 years [3].
3.1. Calcineurin inhibitors (CNI)
The introduction of cyclosporine A (CsA) in the early 1980s
revolutionized clinical lung transplantation [21]. This cyclic
fungal polypeptide binds to cytoplasmic cyclophilins, impair-
ing the enzymatic activity of calcineurin, leading to a
transcription-inhibition of key cytokines (IL-2, IL-4, INF-g,TNF-a). The relatively low concentration of calcineurin in T-
cells renders them especially sensitive to CsA [22]. Amodified
microemulsion formulation (Neoral; Novartis Pharma AG) has
led to better bioavailability, achieving maximum blood levels
more rapidly with less variability [23]. It has been shown that
CsA trough levels correlate inadequately with the effective
systemic exposure, yet, assessing concentrations at 2 h after
intake (C2) better correspond with the effective pharmaco-
kinetic profile [24]. Glanville et al. identified in 50 de novo
lung transplant recipients (including 20 cystic fibrosis
patients) target C2 levels, which were associated with
improved rates of AR and BOS, compared to historic controls:
C2 >800 mg/l at 48 h; 1200 mg/l in month 1; >1000 mg/l in
month 2; > 800 mg/l in month 3; >700 mg/l month 3—6; >
600 mg/l beyond month 6 [25].
Recently, a randomized, placebo-controlled, double-
blind, multicenter trial on efficacy of inhaled cyclosporine
in lung transplant recipients under a conventional triple
immunosuppressive regimen, was published [26]. Although
the study had some limitations, and did not reach its primary
efficacy endpoint (prevention of acute rejection), both
survival and freedom from chronic rejection were signifi-
cantly increased in the CsA arm, compared to placebo [26].
At the 2008 ISHLTmeeting, the same group presented data on
30 transplanted patients, where aerosolized CsA in addition
to conventional immunosuppression significantly preserved
FEV1, versus placebo and historical controls [27]. The
concept of selectively delivering an immunosuppressive
agent to the allograft is intriguing, and may hold future
promise to circumvent systemic side effects associated with
the class of drugs. The increasing interest in this approach is
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Ongoing trials, assessing the use of pharmacological immunosuppressants in lung transplantation.
Purpose/title/identification number Primary endpoint Design Sponsor Participants Enrollment Completion
A prospective single-center
randomized trial of intraoperative
versus postoperative thymoglobulin
in lung transplantation.
NCT00592306
The influence of timing of
thymoglobulin induction (intra-
vs postoperative) on primary
graft dysfunction.
Randomized, single-center,
double-blind, placebo-
controlled.
University of California,
Los Angeles, USA; Genzyme
University of California, Los
Angeles, USA
120 09/2009
Study comparing simulect plus
standard immunosuppression to
standard immunosuppression alone
for the prevention of acute rejection
and bronchiolitis obliterans in lung
transplant. NCT00188825
Proportion of patients who
experience one or more acute
allograft rejections in the first
6 months of treatment
Randomized, double-blind,
single-center, placebo-
controlled, single group
assignment.
University Health Network,
Toronto; Novartis
University Health Network,
Toronto
30 Not specified
Study of EZ-2053 (ATG) in the
prophylaxis of acute pulmonary
allograft rejection. NCT00105183
Rate of efficacy post-
transplant at 6 months.
Prevention, randomized,
double-blind, placebo control,
parallel assignment, safety/
efficacy study.
Fresenius AG Centers in US, Canada, Austria
and Australia
240 12/2011
An open-label treatment use protocol
of cyclosporine inhalation solution
(CIS) in lung transplant recipients.
NCT00633373
Not specified Expanded access. APT Pharmaceuticals, Inc. Universities of California at San
Francisco; Florida, Nemour’s
Children’s Hospital; Maryland,
Medical Center; Children’s
Hospital Boston; Minnesota;
Cleveland Clinic; Pittsburgh
Medical Center
Not specified Not specified
Pilot study of cyclosporine A dry
powder inhalation in lung transplant
patients with bronchiolitis obliterans
syndrome. NCT00378677
Change in FEV1 before/after
the intervention. Pulmonary
deposition and systemic uptake
of CsA.
Non-randomized, single-
center, open label, active
control, single group
assignment.
University Medical Center
Groningen, Netherlands
University Medical Center
Groningen, Netherlands
7 Not specified
This study is to investigate whether
initiation of everolimus together
with reduction of CNI inmaintenance
heart or lung transplant patients
with renal impairment will improve
renal function (NOCTET study).
NCT00377962
Assessment and comparison of
the renal function by measured
glomerular filtration rate
(mGFR) between the
treatment groups, using the
change from baseline to month
12 of treatment. Safety and
efficacy (rate of acute
rejection, BOS worsening).
Randomized, open label,
multi-center, international.
Novartis Nordics 300 Not specified
Comparing de novo enteric coated
mycophenolate sodium with delayed
onset everolimus, both arms in
combination with cyclosporine
(using C2 monitoring) and
corticosteroids for the prevention of
bronchiolitis obliterans syndrome in
heart-lung, bilateral lung and single
lung transplant recipients
(CeMyLungs).
ACTRN12605000141640.
To assess the incidence of
patients with BOS, defined as a
sustained fall (for>1 month) in
maximum FEV1 of 20% or more
(compared to baseline) over 3
years post-transplant.
A 3-year randomised, open
label, multi-center
investigator driven study.
Associate Professor A.
Glanville, St. Vincent’s
Hospital, Darlinghurst,
Australia
European and Australian lung
transplantation centers
320 Not specified
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.underscored by two current ongoing studies (Table 3:
NCT00633373, NCT00378677).
Tacrolimus (Tac, synonymous with FK506; Prograf, Astellas
Pharma, Inc.), a macrolide antibiotic, was adopted as an
immunosuppressant in transplantation medicine in the early
1990s. In analogy to CsA it functions as a CNI, however, through
binding to a distinct immunophilin [28]. In vitro, Tac displays a
50—100 times greater immunosuppressive potency than CsA
[22]. In contrast to CsA, Tac is dosed according to trough (C0)
levels, and bioavailability varies between patients. Recently,
Tac has been introduced as a once daily formulation (advagraf)
in Europe and Canada for the prophylaxis of acute rejection in
liver and kidney transplant recipients [29], yet, so far, no
published data exists on use of this formulation in lung
transplantation. Robust study data comparing efficacy of Tac
versus CsA in pulmonary engraftment is scarce, and to date,
only three prospectively designed trials have been reported
[30—32] (Table 4). Two of them were based on single- or two-
center experience, over 1 or 2 years, enrolling 74 and 133
patients. Only one large international multicenter study has
been performed, with 3-year results presented at the 2008
ISHLTmeeting [32]. Emerging from these investigations, there
seems to be a trend of fewer AR episodes in the presence of
Tac, compared to CsA. Likewise, ISHLT registry data between
2000 and 2005 indicated a slightly lower average number of AR
per year in patients under Tac/mycophenolate mofetil (MMF),
versus CsA/MMF [3]. However, throughout all studies therewas
no significant difference seen in terms of survival between
groups [30—32], and only one trial showeda clear advantage of
Tac over CsA for development of BOS at 2 years [30].
Furthermore, it has to be taken into account that in all trials,
CsA dosing was based on C0, instead of C2 levels, which may
have limited achieving the optimal individual systemic
exposure [25]. Therefore, to accurately investigate state-
of-theart immunosuppressivepotential ofCNIs, there is a need
for large, randomized, multicenter trials, comparing CsA C2-
monitoring versus Tac standard and once daily formulation.
Altogether, short- and long-term immunosuppressive
efficacy as an unambiguous primary endpoint, when
discussing CsA and Tac in recipients of lung allografts,
may not be the adequate measure. Alternatively, the
characteristic side effect profile for the compounds should
be considered. Nephrotoxicity is similar with both drugs
[22], but CsA causes less new-onset diabetes, neurotoxicity
and gastrointestinal complications [22,31]. Tac is asso-
ciated with fewer lipid metabolism disorders, less hyper-
tension, and does not cause hirsutism and gingival
hyperplasia [22]. Based on an individualized approach,
Tac may thus be preferred in recipients with cardiovascular
risk factors, whereas in patients with a history of diabetes
mellitus, CsA would be the CNI of choice. This rationale is
supported by ISHLT registry data, listing hypertension
(85.3%), hyperlipidemia (53.6%) and diabetes mellitus
(35.5%) among the most prevalent morbidities at 5 years
following lung transplantation [3]. Furthermore, pre-
existing diabetes mellitus has been identified as a categoric
risk factor (RR 1.15; p = 0.00489) for 5-year mortality [3].
Revisiting the paradigm of immunosuppressive potency,
greater significance should be attributed to recipient
profiles, choosing CNI based on individual risk factors and
comorbidities.
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Table 5
Key studies analyzing efficacy of Aza versus MMF in lung transplantation.
Author, year Study details n Endpoint Result
Palmer et al., 2001 [45] 6-month, randomized,
prospective, 2 centers.
81 AR, infection, adverse events,
CMV infection, survival.
Similar outcome, no significant
differences between groups.
McNeil et al., 2006 [46] 3-year, prospective,
international, multicenter.
320 Incidence of BOS, AR, survival. Trend toward better survival
at 1 year for MMF, but not at
3 years. Otherwise no sig.
difference. More patients
withdrew from Aza (possible
imbalance on observation time).
Table 4
Key studies analyzing efficacy of CsA versus Tac in lung transplantation.
Author, year Study details n Endpoint Result
Keenan et al., 1995 [30] 2-year, prospective, single-center. 133 Survival, AR episodes, OB development. Similar survival (trend favoring Tac).
Significantly less AR episodes and OB
development with Tac; sig. greater
freedom from OB for Tac.
Treede et al., 2001a [100] 1-year, prospective,
randomized, 2-center.
50 Survival, freedom from AR, numbers of
treated AR.
Survival and freedom from AR slightly
in favor for Tac. Significantly less
patients treated for AR with Tac.
Zuckermann et al., 2003a [31] 1-year, prospective, 2-center. 74 Survival, freedom from AR, numbers of
treated AR, infections.
Similar survival and comparable
freedom from AR between groups.
Trend to more AR episodes and
infections with CsA.
Reichenspurner et al.,
2008 [32]
3-year, prospective, randomized,
multi-center.
249 Incidence of AR, OB and infections. Survival, incidence of AR did not differ
sig. between groups. Trend in favor
for Tac in terms of freedom from BOS.
No difference in overall infections
and renal function.
a These two authors report on the same study — Treede et al. in 2001 published an interim analysis, whereas Zuckermann et al. in 2003 covered the final study
results.3.2. Anti-metabolites
Azathioprine (Aza), initially used to prevent rejection in
recipients of kidney allografts in the 1960s by Murray and co-
workers [33], signified the first breakthrough in immunosup-
pressive therapy and prepared the ground for clinical
expansion of transplantation medicine. 6-Mercaptopurine,
the active metabolite of Aza, inhibits de novo purine and
DNA/RNA synthesis, and T-cell proliferation pathways [34].
After the initiation of successful lung transplantation by
Cooper et al. in the 1980s [35], Aza, together with CsA and
steroids formed the therapeutic backbone of immune
modulation in these patients.
Mycophenolate mofetil (cellcept, Roche AG) has been
used in experimental transplantation since the late 1980s
[36], and in the clinical setting from the early 1990s on [37].
Mycophenolic acid (MPA), the active compound of MMF,
displays a more selective and less toxic effect, compared to
Aza. As a reversible inhibitor of inosine monophosphate
dehydrogenase (IMPDH), MPA impairs the rate-limiting
enzyme in de novo purine synthesis [38]. In contrast to
other blood cells that can utilize the salvage purine synthesis
pathway, proliferating lymphocytes rely heavily on de novo
synthesis. Thus, the key effector component responsible for
cellular and humoral immunity is selectively inhibited [22].
Large prospective randomized trials in other perfused organ
transplants confirmed the superior efficacy of MMF over Aza
in the late 1990s [39,40], and several smaller studies from
single centers versus historical controls, indicated a similartrend in de novo lung transplantation [41—44]. However, only
two randomized prospective trials have been undertaken to
elucidate the value of MMF in pulmonary transplantation
(Table 5): Palmer et al., enrolling 81 participants, in a 6-
month, two-center trial did not find a significant difference in
biopsy-proven acute rejection, incidence of CMV infection or
survival, between MMF versus Aza [45]. Likewise, in the only
international multicenter study, in a follow-up over 3 years in
320 patients, McNeil et al. [46] did not show a significant
difference between these two anti-metabolites for inci-
dences of acute rejection episodes, BOS or for survival.
Concluding from the available study data, and despite its
increasing use [3], the unambiguous proof of the superiority
of MMF over Aza in lung transplantation is still outstanding.
When evaluating the immunosuppressive efficacy of MMF
in the context of rejection prophylaxis in pulmonary
engraftment, drug—drug interactions with CNI have to be
taken into consideration. Since CsA impairs the enterohe-
patic recirculation for MPA, MPA concentrations are lower in
recipients receiving CsA, compared to patients on Tac-based
regimens [47]. Gerbase et al. recently showed in main-
tenance lung transplant recipients that MPA trough levels
decreased by half when MMF was combined with CsA [48].
Optimizing future immunosuppression in lung transplanta-
tion, more effort will have to be directed toward therapeutic
drug monitoring of MMF [49].
Myelosuppression and gastrointestinal adverse events are
the most common encountered side effects of MMF, often
necessitating dose reduction or even temporary discontinua-
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intensified anti-CMV or antibiotic therapy, developing
leucopenia may force treating physicians to lower MMF
exposure, thus compromising on net immunosuppressive
potency. Enteric-coating of MPA (EC-MPS; myfortic, Novartis
Pharma AG) has been introduced to improve tolerability by
decreasing upper gastrointestinal side effects, while main-
taining equivalent MPA exposure and maximal concentration
to MMF [50]. Approved in Europe and the USA in 2004, EC-MPS
has been shown to be equally effective to MMF in de novo
renal transplantation [51], and to be safely used for
converting renal maintenance patients from MMF [52]. Study
results reporting on EC-MPS in lung transplant recipients have
not been published so far. However, in a currently ongoing
international, prospective, randomized trial (Table 3;
ACTRN12605000141640) EC-MPS is being compared to ever-
olimus to assess incidence of BOS over a time period of 3 years
in recipients of pulmonary allografts. Although a MMF
treatment group was not planned to be included in this
study, more data on immunosuppressive efficacy, safety and
tolerability of the enteric formulation in de novo patients
following lung transplantation may be expected.
3.3. mTOR inhibitors
This class of drugs signify the most recent pillar in
immunosuppressive therapy employed in pulmonary trans-
plantation. Rapamycin (sirolimus; Rapammune, Wyeth-
Ayerst), intensely studied in the 1990s, was approved in
the US and Europe in 1999 and 2000, respectively. Binding to
FKBP12 (FK-binding protein 12; interestingly this immuno-
philin also serves as a binding site to Tac, but Tac/FKBP12
targets calcineurin-phosphatase), Rapamycin/FKBP12 then
inhibits a 289-kDa-kinase, mammalian target of rapamycin
(mTOR), eventually blocking G1- to S-phase cell cycle
progression [53]. By interfering with DNA replication at such
an early stage, rapamycin exerts a profound antiproliferative
effect in hematopoietic and non-hematopoietic tissues.
Proliferation of activated T-cells is arrested in the late G1
phase [54] [55], IL-2-dependent and IL-2-independent
stimulation of B-cells is blocked [56] and differentiation
into antibody-producing clones abrogated [57]. In addition,
this class of drugs inhibit smooth muscle cell proliferation
[58], thereby ameliorating long-term graft-specific histolo-
gical changes such as bronchiolitis obliterans [59]. The
promise to curb the dynamics of chronic rejection fuelled an
interest early on to use rapamycin in de novo lung transplant
recipients. Regrettably, in two single-center pilot studies,
out of 19 recipients treated perioperatively with rapamycin,
7 experienced major airway anastomotic complications (5
with partial or complete bronchial dehiscence), and 5
patients died [60,61]. Findings from heart [62], kidney
[63], and liver [64] transplantation trials on de novo
employment of rapamycin indicated similar problems.
Therefore, use of the drug shifted from first-line treatment
to ‘reserve’ immunosuppression in maintenance patients
suffering from particular problems. Calcineurin inhibitor-
associated nephrotoxicity has been alleviated by minimiza-
tion/discontinuation of CNI following the introduction of
rapamycin in several smaller studies [65—67]. Bronchiolitis
obliterans, developing in maintenance patients, has beentargeted with mixed success in some single-/double-center
trials [59,68,69]: although individual responses were
observed across cohorts, small numbers, heterogeneity of
enrolled patients and varying adjunctive immunosuppressive
treatments limit the significance of these results.
At the 2008 ISHLT Meeting, Bhorade et al. presented data
from the AIRSAC trial, a US, multi-center, randomized and
prospective investigation, assessing sirolimus versus
azathioprine (both with Tac and steroids) in 181 lung
transplant recipients [70]. To avoid the potential for wound
healing complications, patients were randomized at 3
months post-transplantation. At 12 months, the incidence
of AR did not differ significantly between groups [70]. The
study was limited by a discontinuation rate of 66% in the
sirolimus arm (vs 47% in Aza) and an imbalance in terms of
pre-transplant diagnosis (more patients suffering from
fibrosis and CF in the sirolimus arm). Interestingly, there
were significantly more overall infections in the presence of
sirolimus, yet, the incidence of CMV infection was signifi-
cantly lower than under Aza [70].
Hyperlipidemia, cutaneous rash, oral ulcers, anemia,
thrombocytopenia, edema, hemolytic uremic syndrome and
delayed wound healing are side effects associated with
rapamycin. Of note, pulmonary toxicity has been reported in
kidney, liver and cardiac transplant recipients, presenting as
interstitial pneumonitis, lymphocytic alveolitis, BOOP or
alveolar hemorrhage [71]. Only a few cases of sirolimus-
associated pneumonitis have been reported in lung trans-
plant patients, yet, since it affects the allograft, arriving at
the appropriate differential diagnosis may constitute a
challenge [72,73]. Most of the described patients improved
without sequelae after discontinuation of the drug, which
indicates an allergic/toxic, probably T-cell mediated etiology
[74]. In addition, overdosing may play a role, since increased
sirolimus troughs have been detected in patients developing
pulmonary toxicity [72,74].
Everolimus (certican, Novartis Pharma AG) is a more
recently introduced mTOR inhibitor, which is distinguished
from rapamycin by a hydroxyl group at position C40.
Approved in Europe in 2004, this proliferation signal inhibitor
displays a modified bioavailability, due to its shorter half life
of 28 h (rapamycin: 62 h) and greater polarity [75,76], as
compared to rapamycin. Although the adverse event profile
overlaps with sirolimus, emerging data in de novo cardiac
transplantation indicate fewer wound healing events in the
presence of everolimus [77]. There are less reports on
pulmonary toxicity-associated events relating to everolimus
[78], and even switching patients from rapamycin to
everolimus for pneumonitis has been shown to alleviate
symptoms [79].
In an international, randomized multicenter study enrol-
ling 213 BOS-free lung transplant recipients, efficacy was
evaluated between azathioprine and everolimus [80].
Although at 12 months the everolimus group showed a
significantly smaller decline in FEV1 and had experienced less
acute rejections, at 24 months only the incidence of acute
rejection episodes still differed significantly between arms
[80]. In addition, there is an ongoing study (NOCTET study),
investigating whether initiation of everolimus together with
reduction of CNI in maintenance heart or lung transplant
patients with renal impairment will improve renal function
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et al. presented their first year interim analysis on delayed de
novo treatment of lung allograft recipients, evaluating
everolimus versus standard of care MMF (with CsA and
steroids) in 100 patients. In the interim analysis, there was a
significant (p=0.043) survival benefit in favor of the ever-
olimus group. As in the study results presented by Bhorade
et al. [70], there were markedly less CMV infections in the
everolimus arm, compared to MMF [81]. A similar designed
European-Australian trial is currently under way, with a
follow-up of 3 years and incidence of BOS as primary endpoint
(Table 3: ACTRN12605000141640).
3.4. Corticosteroids
Corticosteroids are employed during induction, mainte-
nance and anti-rejection therapy in pulmonary transplanta-
tion, emphasizing their crucial role in modulating the host
immune response. They suppress prostaglandin synthesis,
reduce histamine/bradykinin release, decrease vascular
permeability and down-regulate key cytokines by influencing
gene transcription [82]. Used systemically just prior to re-
perfusion of the implanted lung, they are then rapidly
tapered in the early postoperative period. In clinical
practice, steroid withdrawal in pulmonary transplant reci-
pients is rarely undertaken [19,20], reflecting the increased
immunogenicity of the allograft, as compared to kidney or
heart. Impaired glucose tolerance, psychological disorders,
acne, hirsutism and M. Cushing are common side effects, and
glucocorticoids significantly contribute to bone loss following
transplantation, with most of the damage occurring in the
first 12 months, when doses are highest. The prevalence of
osteoporosis among lung transplant patients is 73%, and
fracture rates between 18 and 37% have been reported [83].
Inhaled steroids have been investigated as adjunctive
local immunosuppressive treatment in lung transplantation.
Although reports on single patient outcome were favorable
[84,85], in a randomized, double-blind study on thirty stable
pulmonary transplant patients, no effect on BOS or survival
was seen [86].
4. Acute rejection
Based on the ISHLT registry data, in the first year, 27—40%
of all lung allograft recipients transplanted between July
2004 and June 2007 were treated for acute rejection,
compared to 40—51% of patients receiving their transplants
between January 2000 and June 2005 [3]. Improved diagnosis
and treatment has further decreased the risk of death from
AR from 4.3% within the first 30 days post-transplantation to
1.8% at 1 year [3]. Although multiple non-immunologic
injuries may contribute to development of BOS, the
incidence of AR episodes constitutes one of the major risk
factors [87].
Intravenous steroid pulses (500 mg to 1000 mg/d) for 3 (to
5) days, followed by a temporary increase in maintenance
doses for a few weeks, are the preferred treatment. In the
majority of cases, AR can be reversed, as monitored in
subsequent surveillance bronchoscopies. For refractory AR,
various agents have been used, including polyclonal/mono-clonal antibodies [88], inhaled cyclosporine [89], and
methotrexate [90]. Recurrent AR, representing persistent,
inadequate control of the host immune response, has been
targeted successfully by switching-strategies, e.g. from CsA
to tacrolimus [91], or by adding a mTOR inhibitor.
5. Chronic rejection
Chronic rejection in pulmonary transplantation is synon-
ymous with BOS, and at times the diagnosis of BOS moves into
the therapeutic focus in patients with a history of recurrent/
steroid-refractory AR episodes. Often, though, BO develops
insidiously, in recipients with an uneventful clinical course
following lung engraftment. By 5.6 years post-transplanta-
tion, 51% of patients will have developed BOS, which in turn
accounts for 19.2% of all deaths in patients that survive
between 3 and 5 years [3].
When the diagnosis of BOS is established, the current
therapeutic regimen has to be re-evaluated; modifying
pharmacological immunosuppressive therapy may be pivotal,
but photopheresis [92,93], gastroesophageal reflux [94] and
non-compliance [95] should also be considered. Focusing on
the pharmacological side, augmentation of existing regi-
mens, switching within classes of drugs and/or substitution of
one class for another are conceptual. Steroids may be
transiently increased, and ATG has been advocated [96].
Within-class switches comprise mainly of CsA to Tac and Aza
to MMF [97]. Especially mTOR inhibitors have been used in
several single-center programs to stabilize lung function
after the diagnosis of BOS [59,65].
Recently, themacrolide antibiotic azithromycin has shown
efficacy in improving FEV1 in lung transplant recipients
suffering from BOS. Although a distinct mode of action has
yet to be elucidated, neutrophilia, chemokine release and
bacterial exacerbations have been down-regulated in the
presence of azithromycin [98].
Given the impact of chronic rejection on quality of life and
recipient survival following lung transplantation, the need
for international, randomized and prospective trials, eval-
uating therapeutic regimens for established BOS is obvious.
6. Conclusion
Advances in surgical technique, perioperative manage-
ment and anti-infectious strategy have markedly improved
early morbidity and mortality in recipients of pulmonary
allografts. Yet, during the last 15 years, long-term survival
has failed to increase accordingly [3,99]. The widespread
acceptance of Tac and MPA in lung transplantation occurred
without robust clinical trial evidence, and neither one of
these compounds has unequivocally been proven superior to
their predecessors. Novel as a class, mTOR inhibitors have so
far not shown higher immunosuppressive efficacy or better
containment of emerging BOS, however, several large-scale
prospective studies are currently ongoing. Due to the
pronounced immunogenicity of the pulmonary parenchyma,
side effects of the required high load of immunosuppressants
are considerable, and the ensuing disposition for infectious
complications substantially increases morbidity. In spite of
S. Korom et al. / European Journal of Cardio-thoracic Surgery 35 (2009) 1045—1055 1053the low annual frequency of procedures performed, dis-
tributed across a high number of centers worldwide, efforts
to better co-operate and converge on study design should be
undertaken. Only with the help of large, international,
randomized and prospective trials will it be possible to truly
benchmark future immunosuppressive strategies against
contemporary practices.
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